Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After Percutaneous Coronary Intervention (PCI)
- Registration Number
- NCT00979940
- Lead Sponsor
- Indiana University School of Medicine
- Brief Summary
This research study plans to evaluate the use of atorvastatin in patients with coronary artery disease given immediately before PCI and whether it will decrease the amount of heart damage after PCI.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- patients undergoing revascularization for significant coronary artery disease
- age range 21-85 years
Exclusion Criteria
- non-STEMI, STEMI
- cancer
- renal failure with creatinine>3.0mg/dl
- liver cirrhosis
- lymphoproliferative disorder
- pregnancy
- thrombocytopenia<150'000
- coagulopathy (INR>1.5)
- abnormal liver function tests
- illicit drug use
- history of statin intolerance
- history of rhabdomyolysis
- planned use of Glycoprotein IIb/IIIa inhibitors during PCI
- current therapy with atorvastatin, pravastatin, lovastatin, fluvastatin, or rosuvastatin
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description atorvastatin Atorvastatin Atorvastatin 80mg po given prior to PCI in cath lab
- Primary Outcome Measures
Name Time Method Periprocedural Myonecrosis 16-24 hours post PCI
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Methodist Hospital
🇺🇸Indianapolis, Indiana, United States
Wishard Hospital
🇺🇸Indianapolis, Indiana, United States